Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 10/20 | 0.43 |
| ▸ | EGFR | P00533 | 10/20 | 0.42 |
| ▸ | ABL1 | P00519 | 6/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 5/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 5/20 | 0.40 |
| ▸ | FYN | P06241 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | YES1 | P07947 | 2/20 | 0.40 |
| ▸ | LYN | P07948 | 2/20 | 0.40 |
| ▸ | FGR | P09769 | 2/20 | 0.40 |
| ▸ | BLK | P51451 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693540 | 1.00 | BTK (0.45) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14693485 | 0.98 | BTK (0.45) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14693483 | 0.98 | BTK (0.45) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14706389 | 0.92 | SRC (0.41) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14706396 | 0.92 | BTK (0.48) | BTKSRCEGFRABL1RIPK1 | |
| SCHEMBL14706390 | 0.90 | EGFR (0.44) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL18380727 | 0.90 | SRC (0.42) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14706430 | 0.88 | EGFR (0.42) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL14706422 | 0.88 | RIPK1 (0.41) | BTKSRCEGFRABL1PTK6 | |
| SCHEMBL18380708 | 0.87 | BTK (0.46) | BTKSRCEGFRABL1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013102059-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | BTK 1/4885SRC 43/4885EGFR 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.